| Year |
Citation |
Score |
| 2019 |
Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, Maybaum J, Zalupski MM, Lawrence TS. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900730. PMID 31398082 DOI: 10.1200/Jco.19.00730 |
0.341 |
|
| 2019 |
Cuneo KC, Morgan MA, Zalupski MM, Sahai V, Schipper MJ, Maybaum J, Lawrence TS. Abstract CT235: A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct235 |
0.351 |
|
| 2018 |
Parsels LA, Parsels JD, Tanska DM, Maybaum J, Lawrence TS, Morgan MA. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. Cell Cycle (Georgetown, Tex.). PMID 29895190 DOI: 10.1080/15384101.2018.1475827 |
0.461 |
|
| 2017 |
Parsels LA, Karnak D, Parsels J, Zhang Q, Vélez-Padilla J, Reichert Z, Wahl DR, Maybaum J, O'Connor MJ, Lawrence TS, Morgan MA. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Molecular Cancer Research : McR. PMID 29133592 DOI: 10.1158/1541-7786.Mcr-17-0455 |
0.433 |
|
| 2017 |
Cuneo KC, Morgan M, Schipper MJ, Maybaum J, Al-Hawary M, Simeone DM, Sahai V, Zalupski M, Lawrence TS. Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.4_Suppl.Tps512 |
0.463 |
|
| 2016 |
Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parcels J, Karnak D, Ryan C, Liu N, Maybaum J, Lawrence TS. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. International Journal of Radiation Oncology, Biology, Physics. PMID 26975930 DOI: 10.1016/J.Ijrobp.2016.01.028 |
0.437 |
|
| 2016 |
Parsels LA, Tanska DM, Parsels JD, Zabludoff SD, Cuneo KC, Lawrence TS, Maybaum J, Morgan MA. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle (Georgetown, Tex.). 0. PMID 26890478 DOI: 10.1080/15384101.2016.1148841 |
0.499 |
|
| 2016 |
Cuneo KC, Morgan M, Schipper MJ, Maybaum J, Feng MU, Al-Hawary M, Simeone DM, Olson LD, Sahai V, Zalupski M, Lawrence TS. Abstract CT035: A dose escalation trial of the WEE1 inhibitor AZD1775, gemcitabine, and concurrent radiation in locally advanced pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct035 |
0.425 |
|
| 2016 |
Parsels LA, Karnak D, Parsels JD, Reichert Z, Maybaum J, Lawrence TS, Morgan MA. Abstract 519: Combined inhibition of WEE1 and PARP1 radiosensitizes KRAS mutant non-small cell lung cancers via inhibition of DSB repair Cancer Research. 76: 519-519. DOI: 10.1158/1538-7445.Am2016-519 |
0.472 |
|
| 2015 |
Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia (New York, N.Y.). 17: 757-66. PMID 26585231 DOI: 10.1016/J.Neo.2015.09.006 |
0.465 |
|
| 2014 |
Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5085-96. PMID 25117293 DOI: 10.1158/1078-0432.Ccr-14-1038 |
0.514 |
|
| 2014 |
Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discovery. 4: 280-91. PMID 24550033 DOI: 10.1158/2159-8290.Cd-13-0337 |
0.319 |
|
| 2014 |
Kausar T, Parsels LA, Parsels JD, Karnak D, Davis MA, Maybaum J, Lawrence TS, Morgan MA. Abstract 862: Sensitization of pancreatic cancer to chemoradiation by the Wee1 inhibitor AZD1775 Cancer Research. 74: 862-862. DOI: 10.1158/1538-7445.Am2014-862 |
0.456 |
|
| 2013 |
Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, Zhao L, Greenson JK, Lawrence TS, Maybaum J, Morgan MA. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4412-21. PMID 23804422 DOI: 10.1158/1078-0432.Ccr-12-3748 |
0.458 |
|
| 2013 |
Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y, Morgan MA. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4422-32. PMID 23780887 DOI: 10.1158/1078-0432.Ccr-13-0788 |
0.409 |
|
| 2013 |
Parsels LA, Parsels JD, Morgan MA, Lawrence TS, Maybaum J. Abstract 707: MK1775-mediated gemcitabine sensitization correlates with prolonged DNA damage signaling in S-phase cells. Cancer Research. 73: 707-707. DOI: 10.1158/1538-7445.Am2013-707 |
0.401 |
|
| 2013 |
Wei D, Parsels LA, Davis MA, Zhao L, Maybaum J, Lawrence TS, Sun Y, Morgan MA. Abstract 1582: Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancer cells by modulation of CDC25C. Cancer Research. 73: 1582-1582. DOI: 10.1158/1538-7445.Am2013-1582 |
0.473 |
|
| 2012 |
Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone DM, Maybaum J, Lawrence TS, Morgan MA. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia (New York, N.Y.). 14: 519-25. PMID 22787433 DOI: 10.1593/Neo.12538 |
0.45 |
|
| 2012 |
Karnak D, Parsels LA, Maybaum J, Lawrence TS, Morgan MA. Abstract 1459: Combined inhibition of Wee1 and PARP1 sensitizes pancreatic cancer cells to radiation Cancer Research. 72: 1459-1459. DOI: 10.1158/1538-7445.Am2012-1459 |
0.516 |
|
| 2011 |
Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle (Georgetown, Tex.). 10: 4321-9. PMID 22134241 DOI: 10.4161/Cc.10.24.18661 |
0.496 |
|
| 2011 |
Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, Maybaum J, Lawrence TS, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3706-15. PMID 21482692 DOI: 10.1158/1078-0432.Ccr-10-3082 |
0.441 |
|
| 2011 |
Venkatesha VA, Parsels LA, Parsels JD, Zabludoff SD, Maybaum J, Lawrence TS, Morgan MA. Abstract 3919: Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition Cancer Research. 71: 3919-3919. DOI: 10.1158/1538-7445.Am2011-3919 |
0.392 |
|
| 2011 |
Parsels LA, Tanska DM, Parsels JD, Zabludoff SD, Brown JL, Morgan MA, Lawrence TS, Maybaum J. Abstract 2964: AZD7762-mediated gemcitabine sensitization does not require G2-M checkpoint abrogation in pancreatic cancer cells: Cancer Research. 71: 2964-2964. DOI: 10.1158/1538-7445.Am2011-2964 |
0.441 |
|
| 2010 |
Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J, Lawrence TS. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Research. 70: 4972-81. PMID 20501833 DOI: 10.1158/0008-5472.Can-09-3573 |
0.389 |
|
| 2010 |
Morgan MA, Parsels L, Zhao L, Parsels J, Davis M, Arumugarajah S, Canman C, Zabludoff S, Maybaum J, Lawrence T. Abstract 491: The roles of homologous recombination repair and cell cycle checkpoints in radiosensitization by the Chk1/2 inhibitor, AZD7762 Cancer Research. 70: 491-491. DOI: 10.1158/1538-7445.Am10-491 |
0.5 |
|
| 2010 |
Parsels LA, Morgan MA, Tanska DM, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Zhao L, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Lawrence TS, ... Maybaum J, et al. Abstract 1765: Preclinical optimization of the Chk1/2 inhibitor AZD7762 in combination with gemcitabine in pancreatic cancer Cancer Research. 70: 1765-1765. DOI: 10.1158/1538-7445.Am10-1765 |
0.481 |
|
| 2009 |
Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, Maybaum J. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Molecular Cancer Therapeutics. 8: 45-54. PMID 19139112 DOI: 10.1158/1535-7163.Mct-08-0662 |
0.487 |
|
| 2008 |
Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: A review Clinical Cancer Research. 14: 6744-6750. PMID 18980967 DOI: 10.1158/1078-0432.Ccr-08-1032 |
0.322 |
|
| 2008 |
Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5142-9. PMID 18698032 DOI: 10.1158/1078-0432.Ccr-07-4072 |
0.341 |
|
| 2006 |
Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle (Georgetown, Tex.). 5: 1983-8. PMID 16931916 DOI: 10.4161/Cc.5.17.3184 |
0.509 |
|
| 2005 |
Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Research. 65: 6835-42. PMID 16061666 DOI: 10.1158/0008-5472.Can-04-2246 |
0.494 |
|
| 2004 |
Parsels LA, Parsels JD, Tai DC, Coughlin DJ, Maybaum J. 5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells. Cancer Research. 64: 6588-94. PMID 15374972 DOI: 10.1158/0008-5472.Can-03-3040 |
0.455 |
|
| 2004 |
Morgan MA, Poynter JN, Maybaum J, Lawrence TS. The role of Bcl-XS in radiation sensitivity Radiation Research. 161: 535-539. PMID 15161370 DOI: 10.1667/Rr3169 |
0.471 |
|
| 2004 |
Ensminger W, Knol J, DeRemer S, Wilkinson E, Walker S, Williams D, Maybaum J. Effects of dexamethasone or celecoxib on biliary toxicity after hepatic arterial infusion of 5-fluorodeoxyuridine in a canine model. Cancer Research. 64: 311-5. PMID 14729639 DOI: 10.1158/0008-5472.Can-03-2588 |
0.304 |
|
| 2001 |
Fridman JS, Parsels J, Rehemtulla A, Maybaum J. Cytochrome c depletion upon expression of Bcl-XS. The Journal of Biological Chemistry. 276: 4205-10. PMID 11044452 DOI: 10.1074/Jbc.M008171200 |
0.698 |
|
| 2000 |
Parsels LA, Kowalski MP, Wagner LM, Parsels JD, Maley F, Maybaum J. Escherichia coli thymidylate synthase expression protects human cells from the cytotoxic effects of 5-fluorodeoxyuridine more effectively than human thymidylate synthase overexpression. Cancer Gene Therapy. 7: 1179-87. PMID 10975679 DOI: 10.1038/Sj.Cgt.7700221 |
0.393 |
|
| 2000 |
Hamstra DA, Pagé M, Maybaum J, Rehemtulla A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Research. 60: 657-65. PMID 10676650 |
0.534 |
|
| 1999 |
Rehemtulla A, Hamilton AC, Taneja N, Fridman J, Juan TS, Maybaum J, Chinnaiyan A. A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia (New York, N.Y.). 1: 63-70. PMID 10935471 DOI: 10.1038/Sj.Neo.7900013 |
0.685 |
|
| 1999 |
Fridman JS, Benedict MA, Maybaum J. bcl-X(S)-induced cell death in 3T3 cells does not require or induce caspase activation. Cancer Research. 59: 5999-6004. PMID 10606248 |
0.687 |
|
| 1999 |
Lin HL, Parsels LA, Maybaum J, Hollenberg PF. N-Nitrosodimethylamine-mediated cytotoxicity in a cell line expressing P450 2E1: evidence for apoptotic cell death. Toxicology and Applied Pharmacology. 157: 117-24. PMID 10366544 DOI: 10.1006/Taap.1999.8651 |
0.502 |
|
| 1998 |
Fridman JS, Rehemtulla A, Hofmann A, Blau HM, Maybaum J. Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells. Oncogene. 17: 2981-91. PMID 9881700 DOI: 10.1038/Sj.Onc.1202224 |
0.707 |
|
| 1998 |
Parsels LA, Parsels JD, Wagner LM, Loney TL, Radany EH, Maybaum J. Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. Cancer Chemotherapy and Pharmacology. 42: 357-62. PMID 9771948 DOI: 10.1007/S002800050829 |
0.493 |
|
| 1997 |
Parsels LA, Zellars RC, Loney TL, Parsels JD, Clarke MF, Merchant AK, Lawrence TS, Maybaum J. Prevention of fluorodeoxyuridine-induced cytotoxicity and DNA damage in HT29 colon carcinoma cells by conditional expression of wild-type p53 phenotype. Molecular Pharmacology. 52: 600-5. PMID 9380022 DOI: 10.1124/Mol.52.4.600 |
0.426 |
|
| 1996 |
Tang HY, Weber KL, Lawrence TS, Merchant AK, Maybaum J. Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells. Cancer Chemotherapy and Pharmacology. 37: 486-90. PMID 8599873 DOI: 10.1007/S002800050416 |
0.457 |
|
| 1995 |
Lawrence TS, Davis MA, Chang EY, Canman CE, Maybaum J, Radany EH. Lack of dependence of 5-fluorodeoxyuridine-mediated radiosensitization on cytotoxicity. Radiation Research. 143: 281-285. DOI: 10.2307/3579214 |
0.44 |
|
| 1995 |
Zellars RC, Loney T, Schott AF, Davis MA, Maybaum J, Clarke MF, Lawrence TS. 160 Role of P53 status in radiation sensitivity and cell cycle progression International Journal of Radiation Oncology Biology Physics. 32: 221. DOI: 10.1016/0360-3016(95)97823-J |
0.376 |
|
| 1994 |
Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects International Journal of Radiation Oncology Biology Physics. 29: 519-523. PMID 8005809 DOI: 10.1016/0360-3016(94)90448-0 |
0.451 |
|
| 1994 |
Tang H, Davis MA, Strickfaden SM, Maybaum J, Lawrence TS. Influence of Cell Cycle Phase on Radiation-Induced Cytotoxicity and DNA Damage in Human Colon Cancer (HT29) and Chinese Hamster Ovary Cells Radiation Research. 138. DOI: 10.2307/3578775 |
0.482 |
|
| 1993 |
Lawrence TS, Normolle DP, Davis MA, Maybaum J. The use of biphasic linear ramped pulsed field gel electrophoresis to quantify dna damage based on fragment size distribution International Journal of Radiation Oncology Biology Physics. 27: 659-663. PMID 8226161 DOI: 10.1016/0360-3016(93)90393-A |
0.351 |
|
| 1993 |
Lawrence TS, Maybaum J. Fluoropyrimidines as radiation sensitizers Seminars in Radiation Oncology. 3: 20-28. DOI: 10.1016/S1053-4296(05)80074-8 |
0.341 |
|
| 1992 |
Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells International Journal of Radiation Oncology, Biology, Physics. 22: 499-503. PMID 1735687 DOI: 10.1016/0360-3016(92)90862-C |
0.448 |
|
| 1992 |
Canman CE, Tang H, Normolle DP, Lawrence TS, Maybaum J. Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity Proceedings of the National Academy of Sciences of the United States of America. 89: 10474-10478. PMID 1438236 DOI: 10.1073/Pnas.89.21.10474 |
0.484 |
|
| 1992 |
Lawrence TS, Davis MA, Normolle DP, Maybaum J. A quantitative assay for radiation-induced DNA damage based on DNA fragment size using pulsed field gel electrophoresis International Journal of Radiation Oncology Biology Physics. 24: 177-178. DOI: 10.1016/0360-3016(92)90225-7 |
0.341 |
|
| 1991 |
Maybaum J, Burton EC, Shelton DA, Jing HW, Dusenbury CE, Ensminger WD, Stetson PL. Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines. Biochemical Pharmacology. 42: 131-7. PMID 1829889 DOI: 10.1016/0006-2952(91)90691-W |
0.415 |
|
| 1990 |
Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells Radiation Research. 123: 192-198. PMID 2389005 DOI: 10.2307/3577544 |
0.439 |
|
| 1990 |
Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure International Journal of Radiation Oncology, Biology, Physics. 18: 1393-1398. PMID 2370189 DOI: 10.1016/0360-3016(90)90313-9 |
0.32 |
|
| 1990 |
Maybaum J, Morgans CW, Ting P, Rogers CE. Modulation of the cytotoxic mechanism of 6-thioguanine by 4-amino-5-imidazolecarboxamide. Cancer Chemotherapy and Pharmacology. 26: 168-72. PMID 2357762 DOI: 10.1007/Bf02897194 |
0.437 |
|
| 1989 |
Maybaum J, Ting P, Rogers CE. Prediction of thioguanine-induced cytotoxicity by dual-parameter flow cytometric analysis. Cancer Chemotherapy and Pharmacology. 24: 291-294. PMID 2758558 DOI: 10.1007/Bf00304760 |
0.396 |
|
| 1988 |
Fairchild CR, Maybaum J, Straw JA. Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture. Cancer Chemotherapy and Pharmacology. 22: 26-32. PMID 3396144 DOI: 10.1007/Bf00254176 |
0.43 |
|
| 1988 |
Richardson BC, Cornacchia E, Golbus J, Maybaum J, Strahler JR, Hanash S. N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide. Arthritis & Rheumatism. 31: 995-999. PMID 2457378 DOI: 10.1002/Art.1780310809 |
0.393 |
|
| 1987 |
Maybaum J, Kott MG, Johnson NJ, Ensminger WD, Stetson PL. Analysis of bromodeoxyuridine incorporation into DNA: comparison of gas chromatographic/mass spectrometric, CsCl gradient sedimentation, and specific radioactivity methods. Analytical Biochemistry. 161: 164-71. PMID 3578781 DOI: 10.1016/0003-2697(87)90667-1 |
0.308 |
|
| 1986 |
Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment Biochemical Pharmacology. 35: 3533-3541. PMID 3533081 DOI: 10.1016/0006-2952(86)90623-4 |
0.459 |
|
| 1985 |
Maybaum J, Hink LA, Roethel WM, Mandel HG. Dissimilar actions of 6-mercaptopurine and 6-thioguanine in Chinese hamster ovary cells. Biochemical Pharmacology. 34: 3677-82. PMID 4052107 DOI: 10.1016/0006-2952(85)90230-8 |
0.451 |
|
| Show low-probability matches. |